



Eosinophilic Inflammation

Guest Editors:

Dr. Akira Kanda

Kansai Medical University,
Department of
Otorhinolaryngology, Moriguchi,
Japan

akanda@hirakata.kmu.ac.jp

Dr. David Dombrowicz

EGID, Inserm, CHU Lille, Institut
Pasteur de Lille, U1011, University
of Lille, 59019 Lille, France

david.dombrowicz@pasteur-
lille.fr

Deadline for manuscript
submissions:

31 December 2020

Message from the Guest Editors

Dear colleagues,

The focus of this Special Issue is eosinophilic inflammation such as allergic rhinitis, asthma, chronic rhinosinusitis with nasal polyp, esophagitis, gastroenteritis, and otitis media.

Eosinophils are key contributors to Th2-associated pathologies such as allergic disorders. They also function as effectors in the innate immune response through the expression of Toll-like receptors. In the inflamed site, activated eosinophils exert their effects through cytotoxic mediators, comprising granules (EPO, MBP, ECP, and EDN), cytokines, chemokines, and lipid mediators, resulting in tissue damage. However, little is known about the mechanisms of pathogenesis by activated eosinophils.

Here, we focus not only all clinical investigations involved in eosinophils-derived disorders but also basic on investigations *in vitro* and *in vivo* using animal models.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Vladimir N. Uversky

Molecular Medicine, University of
South Florida, Tampa, USA

Message from the Editor-in-Chief

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access:—free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: Indexed in the Science Citation Index Expanded (SCIE - Web of Science) and in **Scopus**. Citations available in MEDLINE (PubMed), full-text archived in PubMed Central.

Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2020).

Contact Us

Biomolecules
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[@Biomol_MDPI](https://twitter.com/Biomol_MDPI)